
Journal of Medicinal Chemistry p. 5638 - 5645 (2017)
Update date:2022-07-31
Topics:
Hansen, Anders H?jgaard
Sergeev, Eugenia
Pandey, Sunil K.
Hudson, Brian D.
Christiansen, Elisabeth
Milligan, Graeme
Ulven, Trond
The free fatty acid receptor 2 (FFA2/GPR43) is considered a potential target for treatment of metabolic and inflammatory diseases. Here we describe the development of the first fluorescent tracer for FFA2 intended as a tool for assessment of thermodynamic and kinetic binding parameters of unlabeled ligands. Starting with a known azetidine FFA2 antagonist, we used a carboxylic acid moiety known not to be critical for receptor interaction as attachment point for a nitrobenzoxadiazole (NBD) fluorophore. This led to the development of 4 (TUG-1609), a fluorescent tracer for FFA2 with favorable spectroscopic properties and high affinity, as determined by bioluminescence resonance energy transfer (BRET)-based saturation and kinetic binding experiments, as well as a high specific to nonspecific BRET binding signal. A BRET-based competition binding assay with 4 was also established and used to determine binding constants and kinetics of unlabeled ligands.
Hubei Lingsheng Pharmaceuticals Co., Ltd.
Contact:+86-0710-3538058
Address:Xiangyang City Xiangcheng Economic Development Zone, Hubei Province
puyang hongda shengdao new material co.,ltd.
Contact:+86-393- 4896278
Address:No.29 East Zhongyuan Road
Contact:+86-371-86058576
Address:NO.32, Jingsan Road, Zhengzhou, China
Taizhou Chemedir Biopharm-tech Co., Ltd
Contact:+86 523 86200218
Address:G09, No. 1 Avenue China Medical City, Taizhou,Jiangsu, China
Shandong Bolode Bio-Technology Co., LTD
Contact:+86-0531-58966870
Address:136 Jingyi Road,Huaiyin District,Jinan,Shandong,China
Doi:10.1002/adsc.201701068
(2017)Doi:10.1021/acsmedchemlett.7b00126
(2017)Doi:10.1021/acs.joc.7b00438
(2017)Doi:10.1039/c1ob06800h
(2012)Doi:10.1039/c0cp02379e
(2011)Doi:10.1039/c2cc34062c
(2012)